Compugen, Bayer deal progresses with second milestone
December 2014
by  |  Email the author


TEL AVIV, Israel—Compugen recently announced the achievement of a second preclinical milestone for one of the checkpoint protein candidates in its collaboration with Bayer HealthCare, a few months after the company reported reaching the first milestone for the same compound. Bayer and Compugen signed the collaboration and license agreement in August 2013, agreeing to jointly pursue a preclinical research program for antibody-based cancer immunotherapy against two novel immune checkpoint regulators discovered by Compugen. The deal stipulates that Compugen could receive $30 million in milestone payments associated with joint preclinical research for the two checkpoint programs (which includes payments tied to the two milestones achieved so far), with the potential for more than $500 million in milestone payments for both programs.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.